Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects, ≥ 30 years old with either known atherosclerotic coronary or vascular disease OR coronary risk equivalents defined as either:~  * diabetes mellitus,~ * multiple coronary risk factors with a Framingham Risk Score \> 2% per year, or~ * an elevated coronary calcium score (\> 400 for men, \> 200 for women)~* Currently being treated with a statin (Simvastatin 20 mg/d or its equivalent) as monotherapy for treatment of hyperlipidemia~* Recent lipids (within the past 3 months without interval change in the statin regimen) showing both: LDL-C \< 100 mg/dL and HDL-C \< 50 mg/dL (men) or \< 55 mg/dL (women)~Exclusion Criteria:~* Current use of or known intolerance to niacin or ezetimibe~* Known history of liver disease (cirrhosis, chronic hepatitis) or abnormal liver associated enzymes, \> 3x the upper laboratory reference value~* Enrollment in another drug or device research protocol~* Females who are pregnant, expect to get pregnant during the course of the study, or are breastfeeding

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Extended release niacin (Type: ACTIVE_COMPARATOR): None
- Ezetimibe (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).